[ad_1]
In February, the Cabinet of Ministers had already confirmed that Lithuania would buy 616,2 thousand doses of the vaccine under the planned agreement of the European Commission with the manufacturer.
The Ministry of Health, which presented the project, notes that Croatia and Hungary purchase the additional doses in smaller quantities than those allowed on a pro rata basis, so that the remaining quantities are distributed proportionally to the countries.
A preliminary agreement has not yet been received, according to the ministry, the vaccine has not yet been approved by the European Medicines Agency, but the vaccine “is a leader in the protein adjuvant vaccine format.”
The vaccine is scheduled to be available from the second quarter of this year.
“The advantages of the vaccine are the usual storage temperature regime (2 C – 8 C) and the protection of the southern
African variant. Although the efficiency of this option is approximately 50 percent, pharmaceutical companies
The efficacy of the AstraZeneca vaccine for this variant is only 10%, ”says SAM.
So far, the European Medicines Agency (EMA) has approved three vaccines: Pfizer and BioNTech, and Moderna and AstraZeneca, all three used in Lithuania.
According to existing agreements with producers, Lithuania would currently need more than 9 million. dose of vaccine.
In Lithuania, the first dose of the COVID-19 vaccine was administered to a total of 102 thousand people. 691 people, in both doses – 55 thousand. 212 people.
[ad_2]
